An article in the New York Times (January 17,2013) refers to a report from the RAND corporation that suggests that shifting to electronic medical records make increase health care cost. But is also suggests that the data collected from patient datasets may enable faster analysis of the impact of drug interactions. The example describes discovery of a possible link between blood sugar and the joint use of antidepressants and cholesterol reducing drugs when neither by itself had such an effect. Given the benefits from such analysis, can the beneficiaries of such studies i.e., pharmaceutical companies, be required to pay to use the data, thus offsetting the increased costs created ? In a more general supply chain context, should newly available data from sensors or information sensors be monetized to justify their adoption ?